Attendee search 

College Hill Life Sciences is a strategic communications consultancy with over two decades of experience in advising life science organisations worldwide. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting PR, IR and design solutions that showcase each company, product or technology.

We have earned a formidable reputation for incisive board-level communications counsel. Our deep understanding of the needs and drivers of the life science industry and our entrepreneurial approach comes from our teams’ backgrounds in executive management, R&D, Government, sales & marketing, journalism and finance within the life science sector.

With a track record of delivering truly creative programmes, we focus on enhancing the value proposition for companies seeking investment, partnerships or customers. We form long-standing relationships with our clients in biotech, pharma, medical device and diagnostic companies as well as companies that enable scientific research through the supply of enabling technologies and services. We also advise venture investors and service providers.

Our approach is personal, professional and flexible, with value for money as a principle. We are passionate about our clients’ and about making a difference.

Our globally integrated and dedicated life sciences team serve clients around the world from our bases in London, Manchester, Munich, Boston and Sydney.

Oxford Cancer Biomarkers (OCB) is a newly launched company developing tests that predict which cancer patients will respond favorably to existing and emerging cancer drugs allowing treatment to be tailored to individual patients.

The company, which is a spin out from Oxford University, has a patent-protected and validated platform for discovering proteins that are novel chemosensitivity markers for specific drugs.

OCB is developing its biomarkers tests both independently and in partnership with pharma and biotech companies.

Setting the company apart from the crowd, OCB has already implemented a strategic relationship with Quintiles that provides a route for accelerating its novel biomarkers into clinical trials, overcoming the inertia that can sometimes hamper the companion biomarker business model.

The company has secured initial funding via a $5 million equity investment from Quintiles.

OCB's management team, led by Nick McCooke, former CEO of Solexa (the pioneer of next gen sequencing) and Pronota (protein biomarker diagnostic development), includes David Kerr, Professor of Cancer Medicine at the University of Oxford and a recent President of the European Society of Medical Oncology, and Nick La Thangue, Professor of Cancer Biology at the University of Oxford.

ORCA Therapeutics B.V. (ORCA) is developing a pipeline of innovative anticancer therapies based on the highly promising approach of oncolytic viruses. ORCA’s value proposition is based on using its proprietary technologies in the field of Oncolytic Replication Competent Agents. ORCA’s lead product ORCA-010 is a new oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand fold higher oncolytic potency as compared to current state of the art oncolytic adenoviruses in a variety of cancer cell lines and ORCA is currently developing ORCA-010 for its first study in man. 

Numab is a Swiss biotech company focusing on the discovery and development of therapeutic antibodies. Numab is a young company lead by a Management with proven track record in the biotech industry.

Numab applies a high-throughput selection system that increases the antibody discovery success rates by magnitudes and allows to efficiently identify best-in-class and/or first in class antibodies. The discovery engine is particularly well suited to detect antibodies against unconventional targets such as multi-spanning transmembrane proteins (e.g. GPCRs or ion channels).

Numab is pursuing proprietary antibody programs in autoimmune diseases and pain, however, also applies its breakthrough technology to discover highly potent antibodies on behalf of its partners in the pharmaceutical industry.

uniQure is a world-leading gene therapy company. Our lead product, Glybera, received a positive opinion from CHMP in July 2012 and is poised to become the first gene therapy approved in the Western World, capping more than 30 years research in this area.

This positive outcome validates uniQure's AAV platform and, most importantly, the only commercially scalable manufacturing system currently available anywhere.

uniQure's plug-and-play platform offers the opportunity to develop many additional therapies on a platform that is now validated and accepted as safe by regulatory authorities.

uniQure's second programme, for Hemophilia B ($1.5bn market) is in a Phase I/II clinical study and has shown up to 30 months stable, therapeutic expression from a single treatment (NEJM Dec 2011).

Over the coming 6 months further programmes for Porphyria, Parkinson's Disease and Sanfilippo B are expected to enter Phase I/II clinical trials.

uniQure is based in Amsterdam, and backed by Forbion, Gilde, Advent, CAPE and other investors. We would be interested in meeting to discuss potential collaborations and also potential investment opportunities.

The PROTAGEN GROUP is a leading provider of solutions for the

Pharmaceutical and Biotech industries, supporting drug development towards

personalized medicines and GMP compliant protein characterization services

of outstanding quality.

The PROTAGEN GROUP consists of PROTAGEN AG with a clear focus on

diagnostics, and PROTAGEN Protein Services GmbH (PPS) providing GMP

compliant protein analysis.

PROTAGEN AG has developed the proprietary UNIarray® platform to support

patient stratification and the development of Companion Diagnostics (CDx)

using the diagnostic power of autoantibody signatures in blood. We combine

our outstanding know-how in biostatistics and expertise in Protein arrays and

Luminex technology for the development of novel diagnostic assays. Our R&D

focus is on chronic diseases, e.g. neurodegenerative disorders, endometriosis,

autoimmune diseases such as Rheumatoid Arthritis, Systemic Lupus

Erythematosus and Multiple Sclerosis as well as selected cancer indications,

e.g. Prostate-, Breast-, Ovarian-, Colon- and Pancreatic Cancer.

PROTAGEN Protein Services GmbH (PPS)

is a reliable partner for GMP compliant characterization of biotherapeutics

(NBEs) and biosimilar comparability, including stability and release testing.

PPS combines unique expertise in bioinformatics for protein mass spectrometry

with a long track record in protein chemistry and protein analytics in order to

provide the best quality available. In addition, we provide customer support for

all relevant regulatory issues to match with current regulatory requirements

(FDA, EMA, KFDA) for protein drugs.

PledPharma is a Swedish specialty pharma company that develops a new medicine, PledOx®, for prevention of the severe side effects that patients develop as a consequence of chemotherapy treatment of cancer. Many times the treatment cannot be carried out as planned due to very difficult side effects. The current market for supportive cancer care is some SEK 72 billion. PledOx is a medicine within the patent protected substance class PLED, which protects the body’s normal cells against oxidative stress. Oxidative stress is a condition where an overabundance of harmful oxygen molecules (free oxygen radicals) has been formed. We are also evaluating opportunities with PLED substances for other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For more information, please visit www.pledpharma.se